Apotex Corp. announced the launch of Paclitaxel, a generic version of Abrazane, it is a protein-bind particle for injection. These injections have especially been curated for the treatment of people suffering from non-small cell lung cancer, metastatic breast cancer, and adenocarcinoma of the pancreas.
Grifols, S.A. announced the launch of Albutein FlexBag in the concentration of 5% and 25%. It is available in ecologically sustainable packaging, which gives healthcare professionals a more environmentally friendly solution.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5035
Published Date: Jun 16, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising demand for immunoglobulins, higher production of new drugs, and rising cases of liver diseases and coronary issues are the major factors driving the market growth.
The market size of albumin is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Octapharma AG, Bio Med International Pvt. Ltd., Baxter, Apotex Inc., Novozymes, Mitsubishi Tanabe Pharma America Inc., Merck KGaA, Akron Biotech, Thermo Fisher Scientific, and Grifols, S.A
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, grade, application, and by region.
The human serum albumin segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Strict rules and regulations, higher allergic reactions to albumins, and the presence of alternatives in the market are estimated to be the growth-hindering factors for the market expansion.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.